Cabaletta Bio
CompanyUnited States
Cabaletta Bio develops one asset, in phase 1 (CABA-201 in generalized myasthenia gravis). Mostly cell therapy acting on CD19; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 3
- Trials
- 1
- Signal
Pipeline
1Autologous CD19-directed CAR T cells deplete B cells to reduce autoimmune activity.
Phase 1, Cell therapy, CD19, generalized myasthenia gravis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials3
- Signals1
- Similar companies6